5432452026-09-135432452026-09-132026-09-135432452026-09-13in-capmkt:FinancialYear1Member5432452026-09-13in-capmkt:FinancialYear2Member5432452026-09-13in-capmkt:FinancialYear3Member5432452026-09-132026-09-13in-capmkt:FinancialYear1Member5432452026-09-132026-09-13in-capmkt:FinancialYear2Member5432452026-09-132026-09-13in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure543245GLAND PHARMA LIMITEDGLANDNOTLISTEDINE068V01023NewAcquisition (including agreement to acquire)true2026-09-1315:15:002026-09-13GLAND PHARMA LIMITEDListed Entity (self)Gland Pharma USA Inc.0-620000039300000NAtrue2026-09-132026-09-13falsefalsetruePharmaceutical IndustryThe Company’s management has proposed to make Gland US a direct wholly-owned subsidiary (from it being a step-down wholly-owned subsidiary) to remove multiple layers and streamline the corporate structure. There is no material impact on the business or operations of the Company.Nofalse31-10-2026Cash48100000USD 50120848100000011Background: Gland US is a wholly owned step-down subsidiary of the Company and is in the similar line of business of the Company. The principal activity of Gland US is marketing and distribution of pharmaceutical products. Date of Incorporation: March 07, 2022 Last 3 years Turnover: FY26 – NIL FY25 – USD 87,342 FY24 – USD 4,83,808 Country in which the acquired entity has presence: United States of America2025-202602024-202574000002023-202440400000United States of AmericaBackground: Gland US is a wholly owned step-down subsidiary of the Company and is in the similar line of business of the Company. The principal activity of Gland US is marketing and distribution of pharmaceutical products. Date of Incorporation: March 07, 2022 Last 3 years Turnover: FY26 – NIL FY25 – USD 87,342 FY24 – USD 4,83,808 Country in which the acquired entity has presence: United States of America